To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally shift Fabry treatment paradigm STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed can serve as primary basis of approval Rolling submission of the Biologic ...

RICHMOND, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the pricing of an underwritten offering consisting of 35,190,292 shares of its common stock and pre-funded warrants to purchase 17,787,033 shares of its common stock, together with accompanying warrants to purchase 52,977,325 shares of its common stock. The combined offering price of each share of common stock and accompanying warrant is $0.4719. The combined offering pr ...

Core Viewpoint - Sangamo Therapeutics, Inc. (NASDAQ:SGMO) is experiencing a stabilization in its share price following a significant pipeline update, despite a year-long decline of nearly 64% in its stock value [2]. Group 1: Pipeline Update - On December 18, 2025, Sangamo announced the initiation of a rolling Biologics License Application (BLA) submission to the U.S. FDA for isaralgagene civaparvovec (ST-920) aimed at adults with Fabry disease, which could expedite the regulatory process [3]. - The registration STAAR study data supports the BLA, showing ST-920's potential as a one-time, durable gene therapy, with the FDA validating that the mean annualized eGFR slope at 52 weeks can serve as an accelerated approval endpoint [4]. Group 2: Company Overview - Sangamo Therapeutics is a clinical-stage biotech company focused on developing genomic medicines for inherited metabolic, neurologic, and immune diseases, utilizing gene therapy and genome engineering platforms for potentially curative treatments [5].

Core Insights - Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has experienced a significant decline in share price, down nearly 64% over the past year, but has recently stabilized with a 7.19% gain over the last five trading sessions [2] - The company is advancing its lead gene therapy program, seeking accelerated approval for isaralgagene civaparvovec (ST-920) for adults with Fabry disease through a rolling Biologics License Application (BLA) submission to the FDA [3] - The STAAR study data supports the BLA, indicating that ST-920 may serve as a one-time, durable gene therapy, with the FDA validating the use of mean annualized eGFR slope at 52 weeks as an accelerated approval endpoint [4] Company Overview - Sangamo Therapeutics is a clinical-stage biotech company focused on developing genomic medicines for inherited metabolic, neurologic, and immune diseases, utilizing gene therapy and genome engineering platforms [5]

Core Insights - Sangamo Therapeutics has initiated a rolling submission of a Biological License Application (BLA) to the FDA for isaralgagene civaparvovec, a gene therapy for Fabry disease, with expectations to complete the submission by Q2 2026 [1][4] Group 1: Study Results and Regulatory Pathway - The STAAR study demonstrated a positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52 weeks across all dosed patients, which the FDA has agreed will serve as an endpoint for accelerated approval [1][3] - Isaralgagene civaparvovec has shown a favorable safety and tolerability profile, indicating its potential as a one-time, durable treatment for Fabry disease [1][3] - The rolling submission process allows for completed modules of the BLA to be reviewed by the FDA on an ongoing basis, rather than waiting for the entire application to be submitted [2] Group 2: Designations and Company Background - Isaralgagene civaparvovec has received multiple designations from regulatory bodies, including Orphan Drug, Fast Track, and RMAT from the FDA, as well as Orphan Medicinal Product designation from the European Medicines Agency [4] - Sangamo Therapeutics is focused on genomic medicine, aiming to develop treatments for serious neurological diseases and has a pipeline that includes partnered programs and opportunities for investment [7]

Core Viewpoint - Sangamo Therapeutics has received Fast Track Designation from the FDA for ST-503, an investigational treatment for intractable pain due to small fiber neuropathy (SFN), highlighting the urgent need for effective non-opioid alternatives in this area [1][3]. Group 1: Fast Track Designation - The Fast Track Designation is intended to expedite the development and review of therapeutics for serious conditions with unmet medical needs, allowing for more frequent interactions with the FDA [2]. - Companies with this designation may also qualify for Accelerated Approval and Priority Review if they meet specific criteria [2]. Group 2: ST-503 Development - ST-503 is currently being evaluated in the Phase 1/2 STAND study, which is a multicenter, double-blind, randomized, sham-controlled trial aimed at assessing the safety, tolerability, and preliminary efficacy of a one-time intrathecal dose [4]. - Patient recruitment for the STAND study is ongoing, targeting adults with confirmed SFN who have not responded to first-line therapies for at least six months [4]. - Updated nonclinical data presented in September 2025 demonstrated the pharmacology and safety of ST-503, showing durability, potency, and selectivity in nonhuman primates, along with a favorable safety profile [3]. Group 3: Small Fiber Neuropathy (SFN) - SFN is characterized by damage to small nerve fibers, leading to severe chronic pain and autonomic issues, with an estimated prevalence of 53 per 100,000 people in the U.S. [5]. - Current treatment options for SFN are limited, with no long-lasting or curative therapies available, indicating a significant unmet medical need for patients suffering from this condition [5]. Group 4: Company Overview - Sangamo Therapeutics focuses on genomic medicine, aiming to develop treatments for serious neurological diseases lacking adequate therapies [6]. - The company utilizes zinc finger epigenetic regulators and a capsid discovery platform to potentially address neurological disorders and expand delivery methods [6].

Core Viewpoint - Sangamo Therapeutics has received FDA acceptance for a rolling submission of the Biologics License Application (BLA) for isaralgagene civaparvovec (ST-920), a gene therapy for Fabry disease, indicating progress towards potential accelerated approval [1][4]. Company Developments - The FDA's acceptance follows a meeting in October 2025 where Sangamo discussed the efficacy and safety data for ST-920, with the FDA agreeing to use eGFR slope as a primary endpoint for accelerated approval [2][3]. - Sangamo plans to initiate the rolling submission of the BLA later in the fourth quarter of 2025, aiming for a transformative treatment for Fabry disease patients [3][4]. Clinical Study Insights - The Phase 1/2 STAAR study presented at ICIEM2025 showed that isaralgagene civaparvovec could provide meaningful multi-organ clinical benefits and demonstrated a positive mean annualized eGFR slope at 52 weeks across all patients [3][5]. - The STAAR study is a global, open-label, single-dose, dose-ranging clinical trial designed to evaluate the gene therapy in Fabry disease patients, requiring only a one-time infusion [5]. Regulatory Designations - Isaralgagene civaparvovec has received multiple designations from regulatory bodies, including Orphan Drug, Fast Track, and RMAT from the FDA, as well as Orphan Medicinal Product designation from the European Medicines Agency [4].

Neurology Pipeline and Programs - Sangamo is focused on developing genomic medicines for debilitating neurological diseases, leveraging its zinc finger epigenetic regulation technology and AAV capsid discovery platform[3, 4] - ST-503 for small fiber neuropathy (SFN) is in Phase 1/2 clinical trials, with preliminary efficacy data expected in Q1 2027, targeting a market impacting 650,000 people across the US, Europe and Japan[12, 18, 19, 64, 65] - ST-506 for prion disease is advancing towards a CTA submission expected as early as mid-2026, with preliminary efficacy data anticipated from mid-2027, addressing a condition resulting in 1,500 deaths per year across the US, Europe and Japan[12, 21, 22, 33, 87] - The STAC-BBB capsid has demonstrated industry-leading CNS tropism in NHPs, with 700-fold higher transgene expression than benchmark capsid AAV9, and is the subject of license agreements with Genentech, Astellas and Lilly[25, 27, 92] Financial Highlights and Partnerships - Sangamo has received $88 million in cash from STAC-BBB partners to date, with up to $46 billion in potential future milestones and exercise fees assuming exercise of all options and targets, plus additional potential product royalties[26] - As of September 30, 2025, Sangamo had approximately $296 million in cash and cash equivalents, which is expected to fund planned operations into Q1 2026[34, 36] - Sangamo anticipates non-GAAP operating expenses for 2025 to be in the range of $125 million to $145 million[36] - Pfizer exercised a buyout option for a license to use certain zinc finger modified cell lines, resulting in $6 million payment to Sangamo[34] Fabry Disease Program - Positive clinical data from the registrational STAAR study in Fabry disease showed a positive mean annualized eGFR slope of 1965 mL/min/173m2/year (95% CI: -0153, 4083) at 52-weeks across all 32 dosed patients[33] - Sangamo is preparing for an anticipated BLA submission for Isaralgagene civaparvovec as early as the first quarter of 2026, while continuing business development discussions for a Fabry commercialization agreement[28, 33, 124]

Financial Performance - Revenues for the three months ended September 30, 2025, were $581,000, a decrease of $48.8 million (98.8%) compared to $49.4 million in 2024 [181]. - Revenues for the nine months ended September 30, 2025, were $25.3 million, down $24.9 million (50%) from $50.2 million in 2024 [181]. - A net loss of $85.5 million was reported, adjusted for non-cash expenses, with significant changes in liabilities and assets impacting cash flow [213]. Research and Development - The Phase 1/2 STAND study for ST-503, an investigational epigenetic regulator for chronic neuropathic pain, has commenced patient enrollment and recruitment [168]. - A positive mean annualized estimated glomerular filtration rate (eGFR) slope of 1.965 mL/min/1.73m²/year was observed across all 32 dosed patients in the registrational Phase 1/2 STAAR study for isaralgagene civaparvovec, a gene therapy for Fabry disease [168]. - The company expects research and development expenses to increase in the near term due to activities related to the Fabry disease program [189]. Liquidity and Capital Resources - As of September 30, 2025, the company's cash and cash equivalents, along with the $6.0 million from Pfizer and $9.1 million generated through its at-the-market offering program, are estimated to be sufficient to meet liquidity requirements only into the first quarter of 2026 [162]. - Cash and cash equivalents as of September 30, 2025, were $29.6 million, down from $41.9 million as of December 31, 2024 [200]. - The company has approximately $148.7 million remaining available under its Open Market Sale Agreement as of September 30, 2025 [201]. Operating Expenses - Research and development expenses for the three months ended September 30, 2025, were $28.1 million, an increase of $0.4 million (1%) compared to $27.7 million in 2024 [184]. - General and administrative expenses for the three months ended September 30, 2025, were $8.0 million, a decrease of $3.1 million (28%) from $11.0 million in 2024 [184]. - Total operating expenses for the nine months ended September 30, 2025, were $108.4 million, a decrease of $19.9 million (15%) compared to $128.2 million in 2024 [184]. Future Outlook and Concerns - The company has incurred significant losses and expects to continue doing so for at least the next several years as it continues its research and development activities [174]. - The company has substantial doubt about its ability to continue as a going concern for at least the next 12 months, primarily due to significant losses and dependence on additional financing [204]. - The company anticipates continuing to incur operating losses for several years and needs to raise substantial additional capital to fund operations and development [211]. Capital Raising Efforts - The company is actively seeking additional capital through strategic collaborations and other financing sources to support its operations and research [162]. - The company is engaged in discussions for a commercialization agreement for its Fabry disease program but has not yet secured a partner [204]. - The company may face challenges in raising additional capital due to macroeconomic conditions, including the ongoing conflict between Russia and Ukraine [206]. Compliance and Regulatory Matters - The company has been granted a 180-day extension until April 27, 2026, to regain compliance with the minimum bid price requirement on The Nasdaq Capital Market [161]. - The company is preparing for a Biologics License Application (BLA) submission for isaralgagene civaparvovec as early as the first quarter of 2026 [171]. - Future capital requirements could exceed hundreds of millions of dollars per product for regulatory approvals from the FDA [206].